INVESTOR PRESENTATION
Novogen is developing new patient-focused therapies for cancer that have the potential to make a signficant impact.
Dr James Garner, Chief Executive Officer and Managing Director introduces Novogen and shares the transition the business has undergone during his time.
ABOUT THE COMPANY
Novogen Limited (ASX: NRT, NASDAQ: NVGN) is a global oncology biotechnology company, focused on developing cancer treatments for areas with an unmet clinical need.
The Company has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins), each with the potential to yield multiple first in-class drug candidates across a range of oncology indications.
Dr James Garner MA, MBA, MBBS, BSC (HONS)
Chief Executive Officer & Executive Director
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.
Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Novogen in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.
BOARD OF DIRECTORS
BEC, MAICD
Chairman & Non-Executive Director
Deputy Chairman & Non-Executive Director
CA
Non-Executive Director
MNZM
Non-Executive Director
B.SC (HONS), C.DIR
Non-Executive Director
MA, MBA, MBBS, BSC (HONS)
Chief Executive Officer & Executive Director
RESEARCH AND PIPELINE
Novogen now has a well-diversified portfolio of assets, stretching from preclinical to mid-stage clinical
PARTNERING
Novogen is actively seeking partnerships with other companies to develop significant new therapies for patients with cancer.
We aim to build and develop a pipeline of novel therapies, targeting cancer patients poorly served by existing treatment options, through collaborations with scientists and partnerships with other organisations.